999三九品牌怎么样 申请店铺

我要投票 999三九在中草药行业中的票数:1901 更新时间:2025-11-22
999三九是哪个国家的品牌?「999三九」是 华润医药控股有限公司 旗下著名品牌。该品牌发源于广东,由创始人王春城在2007期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力999三九品牌出海!将品牌入驻外推网,定制999三九品牌推广信息,可以显著提高999三九产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

999三九怎么样

华润三九医药股份有限公司(简称“华润三九”)是大型国有控股医药上市公司,前身为深圳南方制药厂。1999年4月21日,发起设立股份制公司。2000年3月9日在深圳证券交易所挂牌上市,股票代码000999。公司于2007年11月底正式进入华润集团。2010年2月,公司名称由“三九医药股份有限公司”正式变更为"华润三九医药股份有限公司"。

华润三九主要从事医药产品的研发、生产、销售及相关健康服务。“999”品牌是中国驰名商标。公司核心产品在国内药品市场上具有相当高的占有率和知名度。三九胃泰、999感冒灵、999皮炎平、999小儿氨酚、999正天丸、999强力枇杷露、气滞胃痛颗粒、999参附注射液、999参麦注射液、舒血宁注射液、华蟾素、999新泰林(注射用五水头孢唑啉钠)、999中药配方颗粒等,单品种年销售均超过亿元人民币。其中,999感冒灵系列销量连续五年位居感冒药市场第一,2011年实现销售额13.6亿元。

2011年,华润三九实现营业收入55.25亿元,较上年同期增长26.58%,实现了公司通过外延式发展促进业务增长的目标。由于成本费用上涨,2011年实现归属于母公司所有者的净利润7.6亿元,同比上年略有降低;经营活动产生的现金流量净额9.55亿元。截至2011年底,公司总资产为76亿元。

当前,华润三九总市值为180亿元,稳定保持在医药行业上市公司前列。上市公司及所属多家生产制造单元为国家高新技术企业。华润三九先后获评“2008年度中国上市公司百强金牛奖”、“2008年度中国上市公司价值百强”、2009年中国制药工业百强”、“2010年度中国最具竞争力医药上市公司20强”等荣誉。2011年,在中国中药协会发布首批中药行业信用评价结果,华润三九获评AAA级中药企业信用荣誉,荣列排行榜榜首。

经过20多年不懈努力,尤其是并入华润集团四年来的大力变革,华润三九现已发展成为国内大型医药类上市公司。华润三九逐步形成了自身的优势和实力。品牌优势:公司具有较强的细分市场产品品牌运作经验,“999”品牌知名度高,目标客户接受度高,是感冒药和皮肤药市场的领导品牌。近期,由世界第二大传播服务集团WPP发布的《2012中国最具价值品牌TOP50强榜单》中,“999”品牌再度入选其中。此次共有“999”、云南白药、同仁堂3个医药品牌入选。

China Resources Sanjiu Pharmaceutical Co., Ltd. (hereinafter referred to as "China Resources Sanjiu") is a large state-owned listed pharmaceutical company, formerly known as Shenzhen Southern pharmaceutical factory. On April 21, 1999, the establishment of a joint stock company was initiated. On March 9, 2000, it was listed on Shenzhen stock exchange with the stock code of 000999. The company officially entered China Resources Group at the end of November 2007. In February 2010, the company name was officially changed from "Sanjiu Pharmaceutical Co., Ltd." to "China Resources Sanjiu Pharmaceutical Co., Ltd.". CR 39 is mainly engaged in the research and development, production, sales and related health services of pharmaceutical products. "999" brand is a well-known trademark in China. The company's core products have a very high share and popularity in the domestic drug market. Sanjiu Weitai, 999 Ganmaoling, 999 piyanping, 999 paediatric aminophenol, 999 Zhengtian pill, 999 Qiangli loquat dew, Qizhi Weitong granules, 999 Shenfu injection, 999 Shenmai injection, Shuxuening injection, Cinobufacin, 999 Xintailin (cefazolin sodium pentahydrate for injection), 999 traditional Chinese medicine formula granules, etc. the annual sales of each single variety are more than RMB 100 million. Among them, the sales volume of 999 Ganmaoling series ranked first in the cold medicine market for five consecutive years, and achieved a sales volume of 1.36 billion yuan in 2011. In 2011, Cr 39 achieved an operating revenue of 5.525 billion yuan, an increase of 26.58% over the same period of the previous year, and achieved the company's goal of promoting business growth through extensive development. Due to the increase of cost, the net profit attributable to the owners of the parent company was RMB 760 million in 2011, slightly lower than the previous year; the net cash flow from operating activities was RMB 955 million. By the end of 2011, the company's total assets were 7.6 billion yuan. At present, the total market value of Cr 39 is 18 billion yuan, which is stable in the forefront of Listed Companies in the pharmaceutical industry. The listed company and its production and manufacturing units are national high-tech enterprises. China Resources 39 has been awarded the "2008 golden bull award of China's top 100 listed companies", "2008 top 100 value of China's listed companies", "2009 Top 100 pharmaceutical industry of China", "2010 Top 20 most competitive pharmaceutical listed companies of China" and other honors. In 2011, the first batch of credit evaluation results of traditional Chinese medicine industry were released in China Association of traditional Chinese medicine, and Cr 39 won the credit honor of AAA level traditional Chinese medicine enterprise, ranking first in the list. After more than 20 years of unremitting efforts, especially the great changes in four years since it was incorporated into China Resources Group, China Resources 39 has developed into a large-scale pharmaceutical listed company in China. China Resources has gradually formed its own advantages and strength. Brand advantage: the company has strong experience in brand operation of products in the market segment, "999" brand has high popularity and high acceptance of target customers. It is the leading brand in cold medicine and skin medicine market. Recently, in the list of top 50 most valuable brands in China 2012 released by WPP, the world's second largest communication service group, "999" brand has been selected again. This time, "999", Yunnan Baiyao and Tongrentang were selected.

本文链接: https://brand.waitui.com/815c90ce7.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

报告:“成分党”成为美妆主流消费群体

毕马威近日发布的《"颜"值经济新篇章:2025年中国美妆市场行业报告》(以下简称《报告》)显示,据调查,58.8%的消费者将产品成分作为购买决策的首要考量因素,“成分党”成为主流消费群体。与此同时,300-500元中端价格带产品市场份额显著提升,而超低价与高端市场则双双承压,反映出消费者在追求"悦己"体验的同时,更加注重产品的实际功效与性价比。(新浪财经)

52分钟前

美联储传声筒:鲍威尔不是降息的最大障碍 美联储内部共识机制濒临瓦解

“美联储传声筒”Nick Timiraos撰文称,特朗普本周表示,他预计在明年5月任命新的美联储主席后,利率将大幅下降。然而,美联储内部反对12月降息声浪越来越大,这意味着他的愿望可能难以实现。无论鲍威尔在12月选择按兵不动还是降息,他都面临近八年任期内最严重的内部阻力。这种分歧可能延续至明年,这意味着,即便更换主席,也并不等于就能确保会有更多降息。一些人担忧,若特朗普无法如愿以偿,可能会采取更激进手段削弱央行独立性,以换取降息。(金十数据APP)

52分钟前

第八届进博会,上海合作交流采购团达成意向采购额7.12亿元

11月21日下午,第八届中国国际进口博览会上海市合作交流采购团总结展示交流活动在闵行区虹桥品汇成功举办。据介绍,本届进博会上海市合作交流采购团采购成交再创新高,共达成意向采购额7.12亿元人民币,比上届提升4.71%,累计意向采购额突破30亿元。采购团规模也进一步扩大,分团总数增至33家,共组织30批次、近760人次走进进博会参观交流,参与企业数量创历年新高。(界面新闻)

52分钟前

《哪吒2》不参加奥斯卡竞逐

当地时间11月21日,奥斯卡奖的主办方美国电影艺术与科学学院公布了符合资格参与最佳纪录长片、最佳国际影片以及最佳动画长片三个奖项竞逐的影片大名单。在最佳动画长片领域,今年有35部影片有资格“冲奥”,意外的是,《哪吒之魔童闹海》并不在其中。另一方面,《罗小黑战记2》榜上有名。(澎湃新闻)

52分钟前

IDEA研究院孵化企业视启未来获近亿元融资

36氪获悉,孵化自IDEA研究院的视觉大模型企业,视启未来(深圳)科技有限公司宣布完成近亿元天使轮融资。本轮由A股上市公司安凯微领投,昊辰资本、德虎资本、元禾璞华、银杏谷资本、力合中科、数字未来、九安智能等机构跟投。

52分钟前

本页详细列出关于999三九的品牌信息,含品牌所属公司介绍,999三九所处行业的品牌地位及优势。
咨询